Why the study?
Do LOX-targeting nanoparticles reduce mammary tumor growth compared to soluble anti-LOX antibody in preclinical models?
Do LOX-targeting nanoparticles reduce mammary tumor growth compared to soluble anti-LOX antibody in preclinical models?
LOX-targeting nanoparticles demonstrate superior efficacy in suppressing mammary tumor growth compared to soluble antibodies in preclinical models.
Supports LOX nanoparticle development for breast cancer; hypothesis-generating with no clinical implications yet.
A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.
No takes yet. Share an insight, caveat, or question.
Kanapathipillai et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: